Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Michele Di Stefano
 -- 2574 2023-03-15 11:16:07 |
2 format
Jason Zhu
 -1 word(s) 2573 2023-03-16 04:36:59 |

Video Upload Options

We provide professional Video Production Services to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Di Stefano, M.; Mengoli, C.; Bergonzi, M.; Corazza, G.R. Bone Mass and Mineral Metabolism in Celiac Disease. Encyclopedia. Available online: https://encyclopedia.pub/entry/42227 (accessed on 26 December 2024).
Di Stefano M, Mengoli C, Bergonzi M, Corazza GR. Bone Mass and Mineral Metabolism in Celiac Disease. Encyclopedia. Available at: https://encyclopedia.pub/entry/42227. Accessed December 26, 2024.
Di Stefano, Michele, Caterina Mengoli, Manuela Bergonzi, Gino Roberto Corazza. "Bone Mass and Mineral Metabolism in Celiac Disease" Encyclopedia, https://encyclopedia.pub/entry/42227 (accessed December 26, 2024).
Di Stefano, M., Mengoli, C., Bergonzi, M., & Corazza, G.R. (2023, March 15). Bone Mass and Mineral Metabolism in Celiac Disease. In Encyclopedia. https://encyclopedia.pub/entry/42227
Di Stefano, Michele, et al. "Bone Mass and Mineral Metabolism in Celiac Disease." Encyclopedia. Web. 15 March, 2023.
Bone Mass and Mineral Metabolism in Celiac Disease
Edit
This entry is adapted from the peer-reviewed paper 10.3390/nu5114786

Osteoporosis affects many patients with celiac disease (CD), representing the consequence of calcium malabsorption and persistent activation of mucosal inflammation. A slight increase of fracture risk is evident in this condition, particularly in those with overt malabsorption and in postmenopausal state. The adoption of a correct gluten-free diet (GFD) improves bone derangement, but is not able to normalize bone mass in all the patients. Biomarkers effective in the prediction of bone response to gluten-free diet are not available and the indications of guidelines are still imperfect and debated.

celiac disease osteoporosis gluten-free diet

1. Introduction

Osteoporosis is a condition characterized by low bone mass and micro-architectural deterioration of bone tissue resulting in enhanced bone fragility and an increase in fracture risk [1]. It affects more than 75 million people in developed countries, causing 8.9 million fractures annually worldwide. Osteoporotic fractures account for 2.8 million disability-adjusted life years annually: to make this even clearer, this index is higher than other conditions, such as breast cancer, gastric cancer and hypertension [2]. There is a general agreement in the literature that more than 75% of untreated adult celiac disease (CD) patients with an overt malabsorption syndrome at diagnosis suffer from a loss of bone mass [3][4][5][6][7][8][9], and this complication also affects about half the patients with subclinical CD, presenting with minimal, transient and apparently unrelated symptoms [3][9], or asymptomatic patients diagnosed because of their first-degree kinship [4].

2. Bone Damage and Mineral Metabolism Derangement in Celiac Disease

Intestinal malabsorption and inflammation contribute to the pathophysiology of bone damage in CD. Villous atrophy is responsible for alterations of intestinal absorption, and a negative calcium balance was shown in CD patients due to several mechanisms: malabsorption of calcium in untreated patients [10], partially reversible after gluten-free diet (GFD) [11]; the reduction of calcium intake [12] also due to a secondary lactose intolerance [13]; and the reduction of intestinal calcium absorption due to its binding to intraluminal unabsorbed fatty acids [10]. Hypocalcemia can induce a compensatory increase of serum levels of parathyroid hormone (PTH), in turn responsible for an increase of bone turnover [7][14]: in untreated CD, serum PTH correlates with markers of both bone synthesis, such as osteocalcin, as well as resorption, like telopeptide of type I collagen (ICTP) [5]. Bone resorption is faster than bone neoformation, resulting in net bone loss and a high turnover osteoporosis [15]. The increase of serum PTH enhances the activity of the renal enzyme 1-α-hydroxylase, which converts 25-vitamin D into 1,25 vitamin D, in order to improve calcium absorption at intestinal level. However, this effort is ineffective, mainly due to the lack in immature enterocytes of celiac mucosa of calbindin [16], a vitamin D-dependent calcium-binding protein, minimizing the role of vitamin D malabsorption [17]. Finally, high levels of 1,25 vitamin D might have the paradoxical effect of increasing bone resorption, as shown in patients with chronic renal failure [4]. Accordingly, vitamin D functions are rarely impaired in untreated CD, as hyperconversion of metabolite 25-vitamin D guarantees adequate levels of the active form 1,25 vitamin D.
Intestinal malabsorption could also lead to some deficits of other minerals, fat and water soluble vitamins that could affect normal bone metabolism. In particular, low levels of zinc were described in non-treated celiac patients [18], and related to low levels of insulin-like growth factor, that are subsequently responsible for derangement in bone metabolism, growth and immune function [19].
This complex network of events is present in both overt symptomatic and subclinical CD to be a disease that is below the threshold of clinical detection without signs or symptoms sufficient to trigger CD testing in routine practice—or it is silent, equivalent to asymptomatic CD patients, even if the extent of bone loss and the alterations of serum levels of indices of bone and mineral metabolism may be less severe than in CD patients with overt malabsorption [3].
More recently, much evidence has also suggested the role of both local and systemic inflammation in the pathophysiology of bone loss in CD, characterized by a chronic increase of both mucosal and serum pro-inflammatory cytokines, in particular TNFα, IL-1 and IL-6 [20][21]. IL-1 and TNFα stimulate osteoclastogenesis and bone resorption [22]; IL-6 has a pivotal role in bone resorption by recruiting osteoclast precursors and stimulating their differentiation [23]. In untreated CD patients, serum IL-6 levels inversely correlate with BMD [21] and directly with PTH and ICTP levels, a marker of bone resorption [24]. Recently, the existence of a complex cytokine imbalance in CD patients, affecting both osteoclast and osteoblast activity was shown: cultures of peripheral blood mononuclear cells of healthy donors with sera of untreated CD patients result in an increase in osteoclast number and IL-6 levels, together with an inhibition of IL-12 and IL-18 [25], two cytokines showing an in vitro inhibitory effect on osteoclastogenesis and osteoclast activity [26][27].
In the last 15 years, great attention has been given to the RANKL/RANK/osteoprotegerin pathway, that is today considered the main signaling system in bone metabolism. The receptor activator of nuclear factor κB ligand (RANKL) is expressed and secreted by osteoblasts; it binds RANK, located on the surface of osteoclast precursors, to induce the differentiation of these cells into mature osteoclasts, promoting bone resorption. Osteoprotegerin (OPG) is also secreted by osteoblasts; it acts as a decoy receptor for RANK and blocks RANK–RANKL interaction [28]. In CD patients, an increased level of OPG and RANKL was described, with an OPG/RANKL ratio significantly lower than controls. Moreover, the OPG/RANKL ratio was correlated with spine BMD [29] and with IL-6 levels [25].
The pathophysiological role of autoantibodies against OPG is also debated, as in a recent paper the presence of these antibodies was detected in a man with CD, high bone turnover and severe osteoporosis not responsive to GFD and to calcium and vitamin D supplementation [30]. This observation was not confirmed by a subsequent study on a large cohort of CD patients on GFD [31].
Further factors are linked to endocrine and reproductive disorders, commonly part of CD clinical presentation. In particular, early menopause and periods of amenorrhea could occur in women, due partly to malnutrition and partly to hormonal imbalance, and could worsen the severity of osteoporosis [32]. In men, hypogonadism was described, due to a reversible androgen resistance [33] and to hyperprolactinemia [34], and considered a possible adjunctive factor risk for osteoporosis [35]. Finally, CD is frequently associated with autoimmune thyroiditis and type I diabetes mellitus [36]: both these disorders are at high risk for osteoporosis [37][38].

2.1. Effect of GFD

Strict adherence to GFD allows BMD improvement but it is not able to normalize it in all cases. Mucosal recovery does not appear to be the only determining variable: in fact, with the same histological response, bone mass normalization is present in celiacs on GFD since early infancy [39] but not always in patients on GFD for the same length of time but diagnosed at a later age. In particular, normalization of BMD levels in childhood CD may be complete as early as after two years of GFD [40]. On the contrary, in adults, many cross-sectional studies demonstrated higher BMD levels in treated vs. untreated CD patients but still lower than in healthy volunteers [3][4][5][6][7][8][9][41][42][43][44]; also the prevalence of alterations of indices of bone and mineral metabolism is lower in treated vs. untreated patients [41][45][46]. These results were shown in patients on GFD for a median duration of 28.5 months [5], in patients on GFD from a mean of 3.6 years [41] and in a group of patients treated for a mean of 16 years, a very long period of GFD [46]. It is therefore evident that the early onset of bone damage, probably before achieving bone mass peak, is an important time point determining GFD-induced bone mass gain. Even longitudinal studies are of little help here, as the longest period of GFD evaluated was 5 years [47]. On the other hand, these studies have provided important information on the kinetic of bone mass recovery with the start of GFD and correlations with the modifications of bone-mineral metabolism parameters. Following a GFD with optimal compliance for a period of one year allows a significant improvement of BMD values, ranging from 5% [6] to 8% [3] according to different studies. These results were confirmed in a larger cohort of patients enrolled at diagnosis and restudied after one year of GFD [8]. In a two-year study, GFD improved not only bone mass but also serum levels of indices of bone and mineral metabolism. BMD improvement was more evident after two years than after one year of GFD, suggesting that a period longer than one year was necessary to point out intrinsic capacities of an individual patient to recover bone mass. Serum levels of propeptide of type I procollagen (PICP) at diagnosis proved to be a strong predictor of bone mass gain after two years, suggesting the possibility of selecting the group of patients with high levels of bone matrix formation activity that is more likely to readily respond to GFD [48]. In a three-year study, BMD increased in 92% of CD patients in GFD with a mean bone mass gain around 3%–4% per year. However, only 12% of patients showed a normalization of BMD. In particular, in a small group of patients, it was evident that relatively good bone mass gain was present during the first year, but was negligible in the subsequent study period [49]. These observations agree with a five-year study showing femoral and lumbar BMD values at five years similar to BMD values at one-year follow-up both in men and women, with the exception of trochanter values, which proved to be higher at five-year measurement than one-year values [47].
In summary, BMD values normalize only in children, when diagnosed early in infancy and if they follow a long-term GFD with optimal adherence. On the contrary, BMD values in adults show a good improvement in the first period, generally around two years, after the institution of a GFD; the improvement is then generally unsatisfactory and treatment with a mineral-active drug should probably be considered. Nevertheless, CD patients show a wide range of response to GFD and risk factors for osteoporosis include old age at diagnosis and the degree of osteopenia in late diagnosis, compliance to GFD, menstrual status, i.e., late age at menarche, early menopause, periods of amenorrhea, low body mass index (BMI), low dietary calcium intake, inadequate physical activity and use of glucocorticoids [4][46][50][51]. What appears to emerge is that as age progresses and, in women as menopause approaches, the ability to recover bone mass seems to diminish, being greatest in childhood and lowest in peri- and postmenopausal women. In this latter subgroup of patients, waiting two or three years to determine the extent of GFD-induced bone mass gain could thus be incorrect and the start of treatment with a mineral-active drug should be earlier, probably at diagnosis.
The availability of predictive markers of GFD-induced bone mass gain could be a solution for this problem, but the mechanism responsible for the unsatisfactory improvement is not completely clear. A persistent reduction of fractional calcium absorption was shown in patients on GFD, besides the improvement of intestinal mucosa architecture [11], and in a subgroup of patients the persistence of a secondary hyperparathyroidism and a significant correlation between serum PTH levels and femoral BMD were shown [11]. The possible role of secondary hyperparathyroidism was suggested by other papers [14][52] but also disproved [53], and the proposed pathophysiological mechanisms for the persistent raise of serum PTH were residual villous atrophy leading to calcium malabsorption [14], a reduction of calcium intake [12], but also a slow reversal of parathyroid hyperplasia [54]. Partial adherence to GFD [49] and incomplete mucosal recovery [51] could also have a role in subgroups of treated patients.
Circulating factors secondary to persistent activation of the mucosal immune system could directly interfere with osteoclastogenesis and osteoblast activity. It was shown that in patients following GFD for a mean period of 40 months [25] the prevalence of bone damage is around 40%, and circulating levels of cytokines (IL-6, IL-1beta, TNF-alfa, TNF-beta, IL-12, IL-18, RANK-L, OPG) are significantly lower than in untreated patients, but significantly higher than in healthy volunteers. In particular, the osteoclastogenic activity of sera from patients on long-term GFD proved to be still significantly higher than sera of healthy volunteers and serum cytokine levels were not correlated to PTH levels [25]. An altered ratio between RANKL and OPG in untreated patients normalizes to healthy volunteer levels in patients on GFD [25][29]. Accordingly, the dietary treatment with GFD alone is not able to completely control the increased osteoclast differentiation and activity present in CD, as confirmed by a strong correlation between OPG/RANKL ratio and BMD [29], and the mechanism responsible for bone damage does not involve PTH. Finally, while a three-year period of GFD determines a significant decrease of IL 6, which is significantly inversely correlated at diagnosis with lumbar BMD, it cannot normalize IL-1β and IL-1 receptor antagonist serum levels [21].
Therefore, persistent inflammation in treated CD patients could have a role in the persistence of bone mass derangement. In particular, the predominant mechanism responsible for bone derangement seems different between short-term and long-term treated CD patients: in the period immediately after diagnosis, the malabsorption of calcium and the consequent hormonal and vitamin D alterations appear to be the prevalent pathophysiological mechanism, their correction allowing a satisfactory bone mass gain, comparable to the effect of administering mineral-active drugs in postmenopausal osteoporosis [55]. Unfortunately, the extent of the loss of bone mass in untreated CD is very often higher than the extent of the recovery induced just by GFD in the early stages of treatment and, once the GFD-induced metabolic surge that occurs in this phase is over, persistent bone loss seems due to the persistent activation of a local mechanism, related to chronic inflammation.

3. Fracture Risk

BMD is only one of the factors that contribute to establishing the extent of fracture risk in osteoporotic patients. Other factors are related to bone mechanical characteristics, such as stiffness of cortical bone, but also to inadequacy of protectors from trauma (body mass, fat and muscle compartments) and to neuromuscular dysfunction [56].
Several studies pointed out the prevalence of fracture in celiac population, but with a very important heterogeneity in methods (study design, sample selection, fracture data collection) and cohorts studied (treated/untreated CD), making available data often inconsistent and difficult to interpret [57]. Most authors agree on the increased prevalence of fracture in CD patients [56][58][59][60][61][62][63][64] and a recent meta-analysis evaluating a total of 20,955 CD patients and 96,777 controls described a risk of fracture 43% greater in CD [65]. Data on fractures were collected by mailed questionnaires, by personal interviews or by medical records; consequently, results on peripheral fractures might be more easily estimated and axial fractures underestimated. Only a cross-sectional study explored the existence of asymptomatic vertebral fractures by spinal X-ray and did not find an increase of vertebral fractures in CD patients [61]. However, if CD patients are subdivided according to the clinical presentation, peripheral fracture risk proves to be higher than controls in patients with overt malabsorption symptom, while it is similar to the general population in subclinical and silent presentation [64]. These data were confirmed in a more recent case-control study, pointing out a higher peripheral fracture risk also in men and underlining again the importance of adherence to GFD [56]. However, to confirm what was said above with respect to pathophysiology, in a population-based study in Olmsted County, CD patients showed a fracture risk twice that of controls, and this figure persisted unchanged during GFD [59].
In general, however, large population-based studies should be interpreted with care, since, for example, in one study on the fracture risk in CD patients on a cohort of 1021 celiac patients, a possible misclassification of patients could have accounted for the negativity of results, as data were extracted from the National Patient Discharge Register, known for a low estimated validity of diagnosis of CD (78%) [66].

References

  1. Consensus development conference: Prophylaxis and treatment of osteoporosis. Osteoporos. Int. 1991, 1, 114–117.
  2. WHO Scientific Group on the Assessment of Osteoporosis at Primary Health Care Levels. In Summary Meeting Report 2004; World Health Organization: Brussels, Belgium, 2007; pp. 1–17.
  3. Corazza, G.R.; Di Sario, A.; Cecchetti, A.; Jorizzo, R.A.; Di Stefano, M.; Minguzzi, L.; Brusco, G.; Bernardi, M.; Gasbarrini, G. Influence of pattern of clinical presentation and gluten-free diet on bone mass and metabolism in adult coeliac disease. Bone 1996, 18, 525–530.
  4. Mazure, R.; Vazquez, H.; Gonzalez, D.; Mautalen, C.; Pedreira, S.; Boerr, L.; Bai, J.C. Bone mineral affectation in asymptomatic adult patients with celiac disease. Am. J. Gastroenterol. 1994, 89, 2130–2134.
  5. Corazza, G.R.; di Sario, A.; Cecchetti, A.; Tarozzi, C.; Corrao, G.; Bernardi, M.; Gasbarrini, G. Bone mass and metabolism in patients with celiac disease. Gastroenterology 1995, 109, 122–128.
  6. McFarlane, X.A.; Bhalla, A.K.; Robertson, D.A.F. Effect of gluten free diet on osteopenia in adults with newly diagnosed celiac disease. Gut 1996, 39, 180–184.
  7. Keaveny, A.P.; Freaney, R.; McKenna, M.J.; Masterson, J.; O’Donoghue, D.P. Bone remodeling indices and secondary hyperparathyroidism in celiac disease. Am. J. Gastroenterol. 1996, 91, 1226–1231.
  8. Valdimarsson, T.; Löfman, O.; Toss, G.; Ström, M. Reversal of osteopenia with diet in adult coeliac disease. Gut 1996, 38, 322–327.
  9. Mustalahti, K.; Collin, P.; Sievänen, H.; Salmi, J.; Mäki, M. Osteopenia in patients with clinically silent coeliac disease warrants screening. Lancet 1999, 354, 744–745.
  10. Molteni, N.; Bardella, M.T.; Vezzoli, G.; Pozzoli, E.; Bianchi, P. Intestinal calcium absorption as shown by stable strontium test in celiac disease before and after gluten-free diet. Am. J. Gastroenterol. 1995, 90, 2025–2028.
  11. Pazianas, M.; Butcher, G.P.; Subhani, J.M.; Finch, P.J.; Ang, L.; Collins, C.; Heaney, R.P.; Zaidi, M.; Maxwell, J.D. Calcium absorption and bone mineral density in celiacs after long term treatment with gluten-free diet and adequate calcium intake. Osteoporos. Int. 2005, 16, 56–63.
  12. Kinsey, L.; Burden, S.T.; Bannermann, E. A dietary survey to determine if patients with celiac disease are meeting current healthy eating guidelines and how their diet compares to that of the british general population. Eur. J. Clin. Nutr. 2008, 62, 1333–1342.
  13. Plotkin, G.R.; Isselbacher, K.J. Secondary disaccharidase deficiency in adult celiac disease (nontropical sprue) and other malabsorption states. N. Engl. J. Med. 1964, 271, 1033–1037.
  14. Valdimarsson, T.; Toss, G.; Löfman, O.; Ström, M. Three years’ follow-up of bone density in adult coeliac disease: significance of secondary hyperparathyroidism. Scand. J. Gastroenterol. 2000, 35, 274–280.
  15. Corazza, G.R.; di Stefano, M.; Maurino, E.; Bai, J.C. Bones in celiac disease: diagnosis and treatment. Best Pract. Res. Clin. Gastroenterol. 2005, 19, 453–465.
  16. Staun, M.; Jarnum, S. Measurement of the 10,000-molecular weight calcium-binding protein in small-intestinal biopsy specimens from patients with malabsorption syndromes. Scand. J. Gastroenterol. 1988, 23, 827–832.
  17. Colston, K.W.; Mackay, A.G.; Finlayson, C.; Wu, J.C.; Maxwell, J.D. Localisation of vitamin D receptor in normal human duodenum and in patients with coeliac disease. Gut 1994, 35, 1219–1225.
  18. Valdimarsson, T.; Arnqvist, H.J.; Toss, G.; Järnerot, G.; Nyström, F.; Ström, M. Low circulating insulin-like growth factor i in coeliac disease and its relation to bone mineral density. Scand. J. Gastroenterol. 1999, 34, 904–908.
  19. Jameson, S. Coeliac disease, insulin-like growth factor, bone mineral density, and zinc. Scand. J. Gastroenterol. 2000, 35, 894–896.
  20. Kontakou, M.; Przemioslo, R.T.; Sturgess, R.P.; Limb, A.G.; Ciclitira, P.J. Expression of tumour necrosis factor-alpha, interleukin-6, and interleukin-2 mRNA in the jejunum of patients with coeliac disease. Scand. J. Gastroenterol. 1995, 30, 456–463.
  21. Fornari, M.C.; Pedreira, S.; Niveloni, S.; González, D.; Diez, R.A.; Vázquez, H.; Mazure, R.; Sugai, E.; Smecuol, E.; Boerr, L.; et al. Pre- and post-treatment serum levels of cytokines IL-1beta, IL-6, and IL-1 receptor antagonist in celiac disease. Are they related to the associated osteopenia? Am. J. Gastroenterol. 1998, 93, 413–418.
  22. Wei, S.; Kitaura, H.; Zhou, P.; Ross, F.P.; Teitelbaum, S.L. IL-1 mediates TNF-induced osteoclastogenesis. J. Clin. Investig. 2005, 115, 282–290.
  23. Raisz, L.G. Local and systemic factors in the pathogenesis of osteoporosis. N. Engl. J. Med. 1988, 318, 818–828.
  24. Di Stefano, M.; Sciarra, G.; Jorizzo, R.A.; Grillo, R.L.; Cecchetti, L.; Speziale, D.; Pichini, L.; Gasbarrini, G.; Corazza, G.R. Local and gonadal factors in the pathogenesis of coeliac bone loss. Ital. J. Gastroenterol. 1997, 29, 31.
  25. Taranta, A.; Fortunati, D.; Longo, M.; Rucci, N.; Iacomino, E.; Aliberti, F.; Facciuto, E.; Migliaccio, S.; Bardella, M.T.; Dubini, A. Imbalance of Osteoclastogenesis-regulating Factors in Patients with Celiac Disease. J. Bone Miner. Res. 2004, 19, 1112–1121.
  26. Horwood, N.J.; Elliott, J.; Martin, T.J.; Gillespie, M.T. IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro. J. Immunol. 2001, 166, 4915–4921.
  27. Yamada, N.; Niwa, S.; Tsujimura, T.; Iwasaki, T.; Sugihara, A.; Futani, H.; Hayashi, S.; Okamura, H.; Akedo, H.; Terada, N. Interleukin-18 and interleukin-12 synergistically inhibit osteoclastic bone-resorbing activity. Bone 2002, 6, 901–908.
  28. Khosla, S. Minireview: The OPG/RANKL/RANK system. Endocrinology 2001, 142, 5050–5055.
  29. Fiore, C.E.; Pennisi, P.; Ferro, G.; Ximenes, B.; Privitelli, L.; Mangiafico, R.A.; Santoro, F.; Parisi, N.; Lombardo, T. Altered osteoprotegerin/RANKL ratio and low bone mineral density in celiac patients on long-term treatment with gluten-free diet. Horm. Metab. Res. 2006, 38, 417–422.
  30. Riches, P.L.; McRorie, E.; Fraser, W.D.; Determann, C.; van’t Hof, R.; Ralston, S.H. Osteoporosis associated with neutralizing autoantibodies against osteoprotegerin. N. Engl. J. Med. 2009, 361, 1459–1465.
  31. Larussa, T.; Suraci, E.; Nazionale, I.; Leone, I.; Montalcini, T.; Abenavoli, L.; Imeneo, M.; Pujia, A.; Luzza, F. No evidence of circulating autoantibodies against osteoprotegerin in patients with celiac disease. World J. Gastroenterol. 2012, 18, 1622–1627.
  32. Ozgör, B.; Selimoğlu, M.A. Coeliac disease and reproductive disorders. Scand. J. Gastroenterol. 2010, 45, 395–402.
  33. Green, J.R.; Goble, H.L.; Edwards, C.R.; Dawson, A.M. Reversible insensitivity to androgens in men with untreated gluten enteropathy. Lancet 1977, 1, 280–282.
  34. Farthing, M.J.; Rees, L.H.; Dawson, A.M. Male gonadal function in coeliac disease: III. Pituitary regulation. Clin. Endocrinol. 1983, 19, 661–671.
  35. Stazi, A.V.; Trecca, A.; Trinti, B. Osteoporosis in celiac disease and in endocrine and reproductive disorders. World J. Gastroenterol. 2008, 14, 498–505.
  36. Di Sabatino, A.; Corazza, G.R. Coeliac disease. Lancet 2009, 373, 1480–1493.
  37. Mosekilde, L.; Eriksen, E.F.; Charles, P. Effects of thyroid hormones on bone and mineral metabolism. Endocrinol. Metab. Clin. 1990, 19, 35–63.
  38. Hofbauer, L.C.; Brueck, C.C.; Singh, S.K.; Dobnig, H. Osteoporosis in patients with diabetes mellitus. J. Bone Miner. Res. 2007, 22, 1317–1328.
  39. Mora, S.; Barera, G.; Beccio, S.; Menni, L.; Proverbio, M.C.; Bianchi, C.; Chiumello, G. A prospective, longitudinal study of the long-term effect of treatment on bone density in children with celiac disease. J. Pediatr. 2001, 139, 516–521.
  40. Mora, S.; Barera, G.; Ricotti, A.; Weber, G.; Bianchi, C.; Chiumello, G. Reversal of low bone density with a gluten-free diet in children and adolescents with celiac disease. Am. J. Clin. Nutr. 1998, 67, 477–481.
  41. Bodé, S.; Hassager, C.; Gudmand-Høyer, E.; Christiansen, C. Body composition and calcium metabolism in adult treated coeliac disease. Gut 1991, 32, 1342–1345.
  42. Valdimarsson, T.; Toss, G.; Ross, I.; Löfman, O.; Ström, M. Bone mineral density in coeliac disease. Scand. J. Gastroenterol. 1994, 29, 457–461.
  43. Walters, J.R.; Banks, L.M.; Butcher, G.P.; Fowler, C.R. Detection of low bone mineral density by dual energy x-ray absorptiometry in unsuspected suboptimally treated coeliac disease. Gut 1995, 37, 220–224.
  44. McFarlane, X.A.; Bhalla, A.K.; Reeves, D.E.; Morgan, L.M.; Robertson, D.A. Osteoporosis in treated adult coeliac disease. Gut 1995, 36, 710–714.
  45. Ferretti, J.; Mazure, R.; Tanoue, P.; Marino, A.; Cointry, G.; Vazquez, H.; Niveloni, S.; Pedreira, S.; Mauriño, E.; Zanchetta, J.; et al. Analysis of the structure and strength of bones in celiac disease patients. Am. J. Gastroenterol. 2003, 98, 382–390.
  46. González, D.; Mazure, R.; Mautalen, C.; Vazquez, H.; Bai, J. Body composition and bone mineral density in untreated and treated patients with celiac disease. Bone 1995, 16, 231–234.
  47. Kemppainen, T.; Kröger, H.; Janatuinen, E.; Arnala, I.; Lamberg-Allardt, C.; Kärkkäinen, M.; Kosma, V.M.; Julkunen, R.; Jurvelin, J.; Alhava, E.; et al. Bone recovery after a gluten-free diet: A 5-year follow-up study. Bone 1999, 25, 355–360.
  48. Corazza, G.R.; di Stefano, M.; Jorizzo, R.A.; Cecchetti, L.; Minguzzi, L.; Gasbarrini, G. Propeptide of Type I procollagen is predictive of posttreatment bone mass gain in adult celiac disease. Gastroenterology 1997, 113, 67–71.
  49. Bai, J.C.; Gonzalez, D.; Mautalen, C.; Mazure, R.; Pedreira, S.; Vazquez, H.; Smecuol, E.; Siccardi, A.; Cataldi, M.; Niveloni, S.; et al. Long-term effect of gluten restriction on bone mineral density of patients with coeliac disease. Aliment. Pharm. Ther. 1997, 11, 157–164.
  50. Pistorius, L.R.; Sweidan, W.H.; Purdie, D.W.; Steel, S.A.; Howey, S.; Bennett, J.R.; Sutton, D.R. Coeliac disease and bone mineral density in adult female patients. Gut 1995, 37, 639–642.
  51. Kemppainen, T.; Kröger, H.; Janatuinen, E.; Arnala, I.; Kosma, V.M.; Pikkarainen, P.; Julkunen, R.; Jurvelin, J.; Alhava, E.; Uusitupa, M. Osteoporosis in adult patients with celiac disease. Bone 1999, 24, 249–255.
  52. Selby, P.L.; Davies, M.; Adams, J.E.; Mawer, E.B. Bone loss in celiac disease is related to secondary hyperparathyroidism. J.Bone Miner. Res. 1999, 14, 652–657.
  53. Lemieux, B.; Boivin, M.; Brossard, J.H.; Lepage, R.; Picard, D.; Rousseau, L.; D’amour, P. Normal parathyroid function with decreased bone mineral density in treated celiac disease. Can.J.Gastroenterol. 2001, 15, 302–307.
  54. Christensen, M.S.; Nielsen, H.E.; Torring, S. Hypercalcemia and parathyroid function after renal transplantation. Acta Med. Scand. 1977, 201, 35–39.
  55. Liberman, U.A.; Weiss, S.R.; Bröll, J.; Minne, H.W.; Quan, H.; Bell, N.H.; Rodriguez-Portales, J.; Downs, R.W., Jr.; Dequeker, J.; Favus, M. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N. Engl. J. Med. 1995, 333, 1437–1443.
  56. Sánchez, M.I.; Mohaidle, A.; Baistrocchi, A.; Matoso, D.; Vázquez, H.; González, A.; Mazure, R.; Maffei, E.; Ferrari, G.; Smecuol, E.; et al. Risk of fracture in celiac disease: Gender, dietary compliance, or both? World J. Gastroenterol. 2011, 17, 3035–3042.
  57. Bianchi, M.L.; Bardella, M.T. Bone in celiac disease. Osteoporos. Int. 2008, 19, 1705–1716.
  58. West, J.; Logan, R.F.; Card, T.R.; Smith, C.; Hubbard, R. Fracture risk in people with celiac disease: A population-based cohort study. Gastroenterology 2003, 125, 429–436.
  59. Jafri, M.R.; Nordstrom, C.W.; Murray, J.A.; van Dyke, C.T.; Dierkhising, R.A.; Zinsmeister, A.R.; Melton, L.J., III. Long-term fracture risk in patients with celiac disease: A population-based study in Olmsted County, Minnesota. Dig. Dis. Sci. 2008, 53, 964–971.
  60. Ludvigsson, J.F.; Michaelsson, K.; Ekbom, A.; Montgomery, S.M. Coeliac disease and the risk of fractures—A general population-based cohort study. Aliment. Pharm. Ther. 2007, 25, 273–285.
  61. Vasquez, H.; Mazure, R.; Gonzalez, D.; Flores, D.; Pedreira, S.; Niveloni, S.; Smecuol, E.; Mauriño, E.; Bai, J.C. Risk of fractures in celiac disease patients: A cross-sectional, case-control study. Am. J. Gastroenterol. 2000, 95, 183–189.
  62. Fickling, W.E.; McFarlane, X.A.; Bhalla, A.K.; Robertson, D.A. The clinical impact of metabolic bone disease in coeliac disease. Postgrad. Med. J. 2001, 77, 33–36.
  63. Davie, M.W.; Gaywood, I.; George, E.; Jones, P.W.; Masud, T.; Price, T.; Summers, G.D. Excess non-spine fractures in women over 50 years with celiac disease: A cross-sectional, questionnaire-based study. Osteoporos. Int. 2005, 16, 1150–1155.
  64. Moreno, M.L.; Vazquez, H.; Mazure, R.; Smecuol, E.; Niveloni, S.; Pedreira, S.; Sugai, E.; Mauriño, E.; Gomez, J.C.; Bai, J.C. Stratification of bone fracture risk in patients with celiac disease. Clin. Gastroenterol. Hepatol. 2004, 2, 127–134.
  65. Olmos, M.; Antelo, M.; Vazquez, H.; Smecuol, E.; Mauriño, E.; Bai, J.C. Systematic review and meta-analysis of observational studies on the prevalence of fractures in coeliac disease. Dig. Liver Dis. 2008, 40, 46–53.
  66. Vestergaard, P.; Mosekilde, L. Fracture risk in patients with celiac disease, crohn’s disease, and ulcerative colitis: A nationwide follow-up study of 16,416 patients in denmark. Am. J. Epidemiol. 2002, 156, 1–10.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Health Care Sciences & Services
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Michele Di Stefano
,
Caterina Mengoli
,
Manuela Bergonzi
,
Gino Roberto Corazza
View Times: 507
Entry Collection: Gastrointestinal Disease
Revisions: 2 times (View History)
Update Date: 16 Mar 2023
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback